Brain natriuretic peptide and severity of disease in non-alcoholic cirrhotic patients

Journal of Gastroenterology and Hepatology (Australia)

Volumn 20, Issue 7, 2005, Pages 1115-1120

  Yildiz, Ramazan ^a,b   Yildirim, Bulent ^a   Karincaoglu, Melih ^a   Harputluoglu, Murat ^a   Hilmioglu, Fatih ^a  

^a INONU UNIVERSITY   (Turkey)

^b INONU UNIVERSITY   (Turkey)

Author keywords

Ascites; Brain natriuretic peptide; Cardiomyopathy; Esophageal varices; Liver cirrhosis

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; FUROSEMIDE; ISOSORBIDE MONONITRATE; PROPRANOLOL; SPIRONOLACTONE;

ADULT; AGED; ALCOHOL LIVER CIRRHOSIS; ARTICLE; ASCITES; BACTERIAL PERITONITIS; BLEEDING; BLOOD PRESSURE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; ECHOCARDIOGRAPHY; ESOPHAGUS VARICES; FEMALE; HEART VENTRICLE SEPTUM DEFECT; HEPATIC ENCEPHALOPATHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; BLOOD PRESSURE; CARDIAC OUTPUT; DISEASE PROGRESSION; ECHOCARDIOGRAPHY; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 21844451930     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2005.03906.x     Document Type: Article

References (24)

1. Moller S, Henriksen JH. Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart 2002; 87: 9-15.
2. Wong F, Liu P, Lilly L, Bomzon A, Blendis L. The role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. Clin. Sci. 1999; 97: 259-67.
3. Pozzi M, Carugo S, Boari G et al. Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology 1997; 26: 1131-7.
4. McDonagh TA, Robb SD, Murdoch DR et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998; 351: 9-13.
5. Mair J, Friedl W, Thomas S, Puschendorf B. Natriuretic peptides in assessment of left-ventricular dysfunction. Scand. J. Clin. Lab. Invest. Suppl. 1999; 230: 132-42.
6. Bettencourt P, Ferreira A, Sousa T et al. Brain natriuretic peptide as a marker of cardiac involvement in hypertension. Int. J. Cardiol. 1999; 69: 169-77.
7. Yoshimura M, Yasue H, Okumura K et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993; 87: 464-9.
8. Qi W, Mathisen P, Kjekshus J et al. Natriuretic peptides in patients with aortic stenosis. Am. Heart J. 2001; 142: 725-32.
9. La Villa G, Romanelli RG, Casini Raggi V et al. Plasma levels of brain natriuretic peptide in patients with cirrhosis. Hepatology 1992; 16: 156-61.
10. Wong F, Siu S, Liu P, Blendis LM. Brain natriuretic peptide: is it a predictor of cardiomyopathy in cirrhosis? Clin. Sci. 2001; 101: 621-8.
11. Henriksen JH, Gøtze JP, Fuglsang S, Christensen E, Bendtsen F, Møller S. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 2003; 52: 1511-17.
12. Bie P, Wang BC, Leadley RJ Jr, Goetz KL. Hemodynamics and renal effects of low-dose infusions of atrial peptide in awake dogs. Am. J. Physiol. 1988; 254: R161-9.
13. Mukoyama M, Nakao K, Hosoda K et al. Brain natriuretic peptide as a novel cardiac hormone in humans: evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide. J. Clin. Invest. 1991; 87: 1402-12.
14. De Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003; 362: 316-22.
15. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension. A meta-analytic review. Hepatology 1995; 22: 332-54.
16. Komeichi H, Moreau R, Cailmail S, Gaudin C, Lebrec D. Blunted natriuresis and abnormal systemic hemodynamic responses to C-type and brain natriuretic peptides in rats with cirrhosis. J. Hepatol. 1995; 22: 319-25.
17. Vogeser M, Jacop K. B-type natriuretic peptide (BNP): validation of an immediate response assay. Clin. Lab. 2001; 47: 29-33.
18. Amarapurkar DN, Parikh SS, Shankaran K et al. Correlation between splenomegaly and oesophageal varices in patients with liver cirrhosis (Letter). Endoscopy 1994; 26: 563.
19. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietrony MC, Williams R. Transection of the esophagus for bleeding esophageal varices. Br. J. Surg. 1973; 60: 649-54.
20. Lucey MR, Brown KA, Everson GT et al. Minimal criteria for placement of adults on liver transplant waiting list. A report of national conference organized by the American Association for the Study of Liver Diseases. Transplantation 1998; 66: 956-62.
21. Lebrec D, Giuily N, Hadengue A et al. Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. J. Hepatol. 1996; 25: 135-44.
22. Rayes N, Bechstein WO, Keck H, Blumhardt G, Lohmann R, Neuhaus P. Causes of death after liver transplantation: an analysis of 41 cases in 382 patients. Zentralbl. Chir. 1995; 120: 435-8.
23. Mair J, Hammerer-Lercher A, Puschendorf B. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin. Chem. Lab. Med. 2001; 39: 571-88.
24. Ahmed SS, Howard M, ten Hove W, Leevy CM, Regan TJ. Cardiac function in alcoholics with cirrhosis: absence of overt cardiomyopathy: myth or fact? J. Am. Coll. Cardiol. 1984; 3: 696-702.